Predictive Oncology Inc. (NASDAQ:POAI) has announced the addition of biopharmaceutical finance industry veteran Andrew Einhorn to its business advisory board.
Einhorn is the chief financial officer at Danforth Advisors, where he helps build up life science companies using institutional knowledge and provides financial advisory services to public and privately held companies.
“Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our business advisory board, and I am very pleased that he has agreed to join,” CEO Raymond Vennare said in a statement “As our momentum continues to accelerate, Andrew’s insights, expertise and perspectives will be invaluable in our persistent efforts to deliver unique solutions to our drug development partners while creating lasting value for our shareholders.”
Einhorn was named interim CFO of Cognition Therapeutics (NASDAQ:CGTX) in August 2022, and before that, he served in the same role at RVL Pharmaceuticals plc and Edge Therapeutics (NASDAQ:EDGE) Inc.
“The AI market for early drug discovery is growing rapidly, and I believe Predictive Oncology is uniquely positioned to be a leader in this emerging industry,” Einhorn said. “I look forward to working alongside senior leadership and the Board of Directors to help this company achieve its full operational and financial potential.”
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel